Evaluating Sorfequiline, Pretomanid, and Linezolid Regimens for Newly Diagnosed Drug-Sensitive Pulmonary Tuberculosis in Adults A Randomized, Multi-Center Trial
Led by Global Alliance for TB Drug Development · Updated on 2026-08-19
100
Participants Needed
12
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of two sorfequiline-based treatment regimens combined with pretomanid and linezolid for adults aged 18 to 65 with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis. This phase 2, randomized, multi-center, partially blinded trial involves about 100 participants in South Africa and Tanzania and aims to assess treatment safety and bacterial culture conversion times.
Participants are randomly assigned to one of two oral treatment groups one receives a loading dose regimen of sorfequiline 200 mg daily for 4 weeks followed by 100 mg daily for 13 weeks, and the other receives sorfequiline 100 mg daily for 17 weeks. Both groups also take pretomanid 200 mg and linezolid 600 mg daily, with the treatment administered once daily with food. The trial includes a screening period up to 11 days before treatment, a 17-week treatment period, and a 52-week follow-up after treatment ends.
During the study, participants will undergo safety monitoring including assessments of adverse events, ECGs, vital signs, lab tests, vision checks, and peripheral neuropathy evaluations. Researchers will also measure treatment efficacy by monitoring time to stable sputum culture conversion and treatment outcomes at 26 and 52 weeks post-treatment. Pharmacokinetics and quality of life are additionally assessed throughout the study duration.
CONDITIONS
Brief Title
Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB
Research Team
L
Leandra Lombard
M
Morounfolu Olugbosi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with drug-sensitive pulmonary tuberculosis defined by rapid sputum test
Newly diagnosed or untreated for at least 3 years following previous TB cure
Not capable of childbearing or using effective birth control methods
Body weight of at least 35 kilograms
You will not qualify if you...
Karnofsky score less than 60 at screening
Evidence of extrapulmonary tuberculosis
Cardiovascular issues or risk factors for QT prolongation
Pregnant or breastfeeding
Laboratory abnormalities as defined by the study protocol
For HIV-positive participants: CD4+ count below 200 cells/µL
WHO Clinical Stage 4 HIV disease
Refusal to use specific antiretroviral therapy if indicated
Known intolerance or contraindication to the antiretroviral regimen DTG/TFV/3TC
Your Study Journey
Screening
Duration - Up to 11 days
Participants are screened for eligibility to participate in the trial.
1 visit
Treatment
Duration - 17 weeks
Participants receive one of two sorfequiline-based oral regimens combined with pretomanid and linezolid, taken once daily with food for 17 weeks.
Regular visits during treatment
Follow-up
Duration - 52 weeks
Participants are monitored for safety and treatment outcomes for 52 weeks after finishing treatment.
Periodic follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 18F-Fibroblast Activation Protein Inhibitor 18F-FAPI-74 PETCT Scans in Adults with Pulmonary Tuberculosis to Detect Lung Fibrosis
Screening for Tuberculosis in High-Risk Groups Living in Barcelona
Double-blind, Randomized, Placebo-controlled Trial of 40 mg Atorvastatin to Reduce Lung Inflammation After Tuberculosis Treatment in Adults With and Without HIV
Monitoring Tuberculosis Treatment Using Blood Tuberculosis DNA Levels
A Study on Mycobacterium Tuberculosis Cell-free DNA to Track Treatment Response
Evaluating Doxycycline to Prevent Lung Scarring and Improve Breathing in Adults with Advanced Pulmonary Tuberculosis in a Double-Blind Randomized Trial
Digital Health Education and Reminder Intervention to Improve Tuberculosis Preventive Therapy Among Close Contacts in South Ethiopia
Individualized Dosing Using Model-Informed Precision Dosing for Adults with Pulmonary Tuberculosis
Evaluation of Fibroblast Activating Protein FAP PETCT Imaging in Adults with Pulmonary Tuberculosis to Assess Lung Fibrosis and Damage
Phase 1 Study to Evaluate Safety and Immune Response of the TB Vaccine QTP101 ID93GLA-SE in Adults Aged 55 to 74 Who Have Been Vaccinated with BCG
Short-course Rifapentine-based Treatment for Drug-sensitive Pulmonary Tuberculosis in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009).